HuR-miR-26a/b. In breast cancer, the resistance to tamoxifen treatment is associated with a competition between HuR and miR-26a/b, which regulates Erb-B2 receptor tyrosine kinase 2 (ERBB2) [59]. This evidence concerns the gene ERBB2 and breast cancer.